Michael Hung

Dr. Michael Hung

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2024 in Urology
Verified
Journal Article
Closed access
MHMichael Hung
Michael Hung
ARAshley E. Ross
Ashley E. Ross
ELEric V. Li
Eric V. Li
CPChristian P. Pavlovich
Christian P. Pavlovich
SFSean A. Fletcher
Sean A. Fletcher
JHJim Hu
Jim Hu

25 December 2018 in Surgery Research and Practice
Verified
Journal Article
Open access
PDF file
CDColin Dunn
Colin Dunn
EEEmmanuel U. Emeasoba
Emmanuel U. Emeasoba
MHMichael Hung
Michael Hung
AHAri Holtzman
Ari Holtzman
EBEran Bellin
Eran Bellin
SGStuart Greenstein
Stuart Greenstein
Background. Expanded criteria donor (ECD) kidneys are commonly used but are associated with increased graft failure. Graft failure is in turn related to rehospitalization within thirty days post transplant. Our goal was to determine whether ECD kidneys independently lead to rehospitalization within 30 days, 1 year, and 2 years after transplant.Methods. All adult first-time recipients of deceased donor kidneys transplanted from 2003–2012 at our center were reviewed. Models included demographics, medical comorbidities, center for disease control high-risk kidney, ECD kidney, ischemia times, cause of renal failure, immunosuppressive regimen, positive psychiatric screening, alcoholism, surgeon, year the transplant was performed, years on dialysis before transplant, and the number of inpatient hospitalizations within 6 months prior to transplant. We conducted Andersen–Gill modeling and propensity score matching followed by logistic regression. We also used multivariable linear regression to predict average length of stay during rehospitalization.Results. More ECD patients had a rehospitalization at 1 year (70.3% versus 59%, log-rank testp=0.014). Thirty-day and 2-year time marks were not significant. Andersen–Gill models predicting successive hospitalizations yielded HR of 1.42 (p=0.002) and 1.32 (p=0.015) for ECD patients at 1 and 2 years of after transplantation, respectively. Propensity score matching and logistic regression showed a significant relative risk of 1.630 at one year (p=0.033) and 1.313 at two years (p=0.268). There was no significant association between ECD and subsequent lengths of hospital stay.Conclusion. Receiving an ECD kidney is independently associated with multiple readmissions within 2 years of transplant but unrelated to length of stay.

17 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
AHAaron Huang
Aaron Huang
WWWayne C. Waltzer
Wayne C. Waltzer
MHMichael Hung
Michael Hung
FDFRANK S. DARRAS
FRANK S. DARRAS
AKAdam Michael Kressel
Adam Michael Kressel
VRVictor Romanov
Victor Romanov
Background and Objectives: Bladder cancer (BCa) is characterized by high rates of recurrence and progression, underscoring the need for reliable non-invasive biomarkers. Circular RNAs (circRNAs) are covalently closed non-coding RNAs generated by back-splicing and are stable in biological fluids, including urine. Increasing evidence implicates circRNAs in BCa pathogenesis. However, identification of clinically relevant circRNAs remains challenging. This study aimed to streamline circRNA selection and identification of functional urinary circRNAs for potential use as biomarkers for BCa monitoring. Methods: Using a database-screening approach, we identified circRNAs with high predicted affinity (TDMD score > 1.1) to miR-101-3p (a tumor-suppressive microRNA in BCa). In addition, candidate circRNAs were prioritized based on the following: (i) derivation from genes involved in BCa tumorigenesis; and (ii) origination from exonic or long non-coding RNA sequences. The potential contribution of Argonaute-2 (Ago2) binding sites to circRNA activity or potential usage as biomarker was also evaluated. Expression levels were assessed in urine samples and BCa cell lines, and functional relevance was examined using molecular and cellular assays. Results: circCIAO1(5) and circMALAT1 fulfilled prioritization criteria and exhibited distinct Ago2-binding site profiles. Both circRNAs were upregulated in urine from BCa patients and in aggressive BCa cell lines and showed differential expression between remission and recurrent disease. CircCIAO1(5) demonstrated higher-affinity binding to miR-101-3p, while both circRNAs interacted with miR-101-3p and Ago2. Functional assays revealed enhanced proliferation, motility, and invasion upon circRNA overexpression, consistent with miR-101-3p sequestration and reduction in depression of its target oncogene—EZH2. Conclusions: circCIAO1(5) and circMALAT1 are promising candidates as urinary biomarkers for noninvasive BCa monitoring, illustrating the value of bioinformatics-guided determination of circRNA as potential biomarkers and significance of circRNA-mediated regulatory mechanisms in BCa biology.

30 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
CZChunlian Zhong
Chunlian Zhong
LYLifeng Yin
Lifeng Yin
MHMichael Hung
Michael Hung
Shanshan YaoShanshan Yao
Shanshan Yao
MTMenghuan Tang
Menghuan Tang
Zhaoqing CongZhaoqing Cong
Zhaoqing Cong
Urinary cancers present a severe clinical challenge due to high recurrence rates. Standard intravesical therapies suffer from limited efficacy because of the urinary tract’s robust physiological defenses, namely, the dynamic washout effect during voiding and highly restrictive urothelial barriers, such as the anti-adhesive glycosaminoglycan layer and intercellular tight junctions. This review aims to explore how biomimetic engineering can overcome these obstacles by transitioning drug delivery from passive carriers to active, nature-inspired systems. We conducted a comprehensive review of the recent literature focusing on biomimetic strategies for intravesical drug delivery and urinary cancer theranostics. The analyzed approaches are categorized into chemical biomimicry (such as adhesion and camouflage) and structural/functional biomimicry (including adaptive devices and microrobots). Biomimetic strategies significantly enhance targeted drug retention and tissue penetration. Chemical biomimicry, utilizing mussel-inspired catechol chemistry and cell membrane camouflage, effectively bypasses the urothelial anti-adhesive defenses and reduces the immune clearance. Structural and functional biomimicry, such as naturally derived carriers and actively propelled magnetic or biohybrid microrobots, enables the precise spatial localization and controlled payload release in dynamic fluid environments. Furthermore, lab-on-a-chip technologies and patient-derived organoids (PDOs) offer scalable platforms for screening cargo-specific efficacies and tailoring treatments, providing a crucial bridge to personalized precision medicine. Integrating nature-inspired designs with advanced nanotechnologies provides a highly promising pathway with which to overcome the mechanical and biological barriers of the urinary tract. These biomimetic innovations hold the potential to shift the therapeutic paradigm for urinary oncology, paving the way for more efficient, targeted, and personalized precision medicine.